JCR Pharmaceuticals Co (FRA:JCR) Tariff Resilience Score: 0/10 (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JCR JCR Pharmaceuticals Co Ltd FRA:JCR
47 GF Score
Price €2.52
GF Value €4.19
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is JCR Pharmaceuticals Co Tariff Resilience Score?

JCR Pharmaceuticals Co has the Tariff Resilience Score of 0, which implies that the company might have .

JCR Pharmaceuticals Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes JCR Pharmaceuticals Co might have .

JCR Pharmaceuticals Co  (FRA:JCR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

JCR Pharmaceuticals Co Tariff Resilience Score Related Terms

FRA:JCR
47GF Score
JCR Pharmaceuticals Co Ltd FRA:JCR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is JCR Pharmaceuticals Co (FRA:JCR) Overvalued in 2026?

Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued. The current stock price of €2.52 is trading 39.9% below its estimated GF Value™ of €4.19. GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for FRA:JCR:

  • Tariff Resilience Score: 0
  • GF Value™: €4.19 vs. price of €2.52 (39.9% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:JCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JCR Pharmaceuticals Co Business Description

Other Exchanges JCRRF:USA4552:Japan
Address 3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
47GF Score

Get the complete analysis for FRA:JCR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price
€4.19
GF Value